About Earli
Earli is a Healthcare company based in San Francisco (United States) founded in 2018 by Sam Gambhir, David Suhy, and Cyriac Roeding. Early cancer detection tests are developed using synthetic biomarkers. It operates on a HealthTech model. Earli has raised $40 million across 2 funding rounds from investors including Accenture, Khosla Ventures and Perceptive Advisors. The company has 38 employees. Its chief executive, as recorded, is Cyriac Roeding. Earli offers products and services including Synthetic Biomarkers and Programmable Genetic Constructs. Its focus areas include Biotechnology and Cancer Diagnostics and Therapeutics. Its legal entity is Earli Inc. Its competitors include GRAIL, Color and Delfi Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Earli is engaged in developing innovative solutions for early cancer detection and therapy. Programmable genetic constructs are created to activate only in cancer cells, forcing them to produce therapies that lead to self-destruction. Synthetic biomarkers are utilized to identify hidden cancer at its earliest stages. The company operates within the biotechnology sector, addressing critical challenges in cancer diagnostics and treatment. Partnerships with organizations like Accenture are established to advance their mission. Recognition as a global innovator by the World Economic Forum is received, highlighting their impact in the healthcare industry.
- Total Equity Funding$40M (USD)
in 2 rounds
- InvestorsAccenture
& 9 more
- Employee Count38
Products & Services of Earli
Earli offers a comprehensive portfolio of products and services, including Synthetic Biomarkers and Programmable Genetic Constructs.
Synthetic biomarkers are used for early cancer detection.
Genetic constructs are designed to target cancer cells.
Funding Insights of Earli
Earli has successfully raised a total of $40M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $40M
- Total Rounds 2
- First Round $40M
(Jan 2021)
- Investors Count 10
All 2 funding rounds of Earli with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | Series A | – | Accenture | – | |
| Jan 2021 | $40M | Series A | – | Khosla Ventures |
10 investors in total: 6 institutional and 4 angel.
Investors in Earli
Earli has secured backing from 10 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Accenture, Khosla Ventures and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
IT and management consultancy services are provided globally. | 1989 | accenture.com | Dublin, Ireland | |
Active, long-term growth equity investments are provided globally. | sandscapital.com | Arlington, United States | ||
RM Rahul Mehta | Angel investor, founder of multiple ventures, focused on tech startups | unknown_4c2845afb3044a7cb | ||
SB Shlomo Ben-Haim | Israeli entrepreneur, angel investor, and founder of multiple medtech companies. | unknown_7c8beb6ec8ce40ac8 | ||
JB Jim Breyer | Venture capitalist, founder of Breyer Capital, early Facebook investor | unknown_89bff593acd7462a8 | ||
RM R. Martin Chavez | unknown_c88c09975d82474d9 |
Investor details for Earli
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Earli
34 people are tracked at Earli (8 in leadership, 14 in board & advisors, 12 in team); the tracked headcount is 38.
| Name | Role | Group |
|---|---|---|
Sam Gambhir | Co-Founder | Leadership |
David Suhy | Co-Founder | Leadership |
Cyriac Roeding | Co-Founder & CEO | Leadership |
Sashikanth Banappagari | Vice President & Head - CMC | Leadership |
Blaine McCarthy | Associate Director, Delivery | Leadership |
Badri Ananthanarayanan | VP Of Platform | Leadership |
Nadege Morisot | Director In Vivo Translational Biology | Leadership |
Jeffrey Kuan | Associate Director, Process Development | Leadership |
Alex Parker | Advisor | Board & advisors |
Marty Pomper | Advisor | Board & advisors |
Jim Allison | Advisor | Board & advisors |
Charlie Rudin | Advisor | Board & advisors |
Jamie McGurk | Advisor | Board & advisors |
Lee Hartwell | Advisor | Board & advisors |
Bob Langer | Advisor | Board & advisors |
Phil Greenberg | Advisor | Board & advisors |
Judy Garber | Advisor | Board & advisors |
Adam Bass | Advisor | Board & advisors |
Mark Jacobstein | Advisor | Board & advisors |
Aruna Gambhir | Advisor | Board & advisors |
14 more people are available in the full profile.
Complete people profiles for Earli
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Earli
3 dated milestones of Earli across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Earli is founded.
- Funding First funding round of $40.0M.
- Funding Latest funding round, Series A,.
Competitors of Earli
Earli has 3 listed competitors in our database, 3 of them funded. They include GRAIL, Color and Delfi Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | Provider of DNA sequencing for cancer detection |
Detailed competitors of Earli
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Earli
The website of Earli (earli.com) receives about 2.3K visits a month and ranks #7,560,153 among all websites worldwide, #7,063 in Biotechnology and Pharmaceuticals.
- Monthly visits2.3K
▲ 11.7% vs previous month
- Global rank#7,560,153
among all websites
- Category rank#7,063
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.8
- Average visit37 sec
- DevicesDesktop 37% · Mobile 63%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Earli (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Earli
Complete news archive for Earli
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Earli
Earli was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Earli is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Cyriac Roeding is the CEO of Earli, as recorded in our data. They have also founded this company.
Earli is a funded company, having raised a total of $40M across 2 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Jan 2021.
Earli has 38 employees.
Earli is engaged in developing innovative solutions for early cancer detection and therapy. Programmable genetic constructs are created to activate only in cancer cells, forcing them to produce therapies that lead to self-destruction. Synthetic biomarkers are utilized to identify hidden cancer at its earliest stages. The company operates within the biotechnology sector, addressing critical challenges in cancer diagnostics and treatment. Partnerships with organizations like Accenture are established to advance their mission. Recognition as a global innovator by the World Economic Forum is received, highlighting their impact in the healthcare industry.
Earli's top competitors include GRAIL, Delfi Diagnostics and Color.
Earli offers Synthetic Biomarkers and Programmable Genetic Constructs.
Earli has 10 investors. Key investors include Accenture, Khosla Ventures, Perceptive Advisors, Casdin Capital, and Andreessen Horowitz.
Earli operates through Earli Inc..